JPRN-UMIN000007841
Completed
未知
Phase I study of immuno-Cell therapy for advanced and recurrent esophageal squamous cell carcinoma - Phase I study of immuno-Cell therapy for advanced and recuerent esophageal squamous cell carcinoma
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Advanced and recurrent esophageal squamous cell carcinoma
- Sponsor
- Toho University
- Enrollment
- 5
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\.patient who has severe complication 2\.patient who has bleeding tendency 3\.patient who has active infectious disease 4\.concomitant treatment with steroids 5\.HBs antigen, HCV antibody, HIV antibody or HTLV\-1 antibody is positive 6\.patient who has activated autoimmune disease 7\.patient who was judged to be unsuitable for this clinical trial
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 1
A phase I clinical study of immune cell therapy with MAGE-A4- or Survivin-specific Th1 cells for patients with refractory virulent tumorsRefractory cancer patients (MAGE-A4- or Survivin-expressing, non origin-limited) or the patients who refuse standard cancer therapyJPRN-UMIN000004828Department of General Surgery, Hokkaido University Graduated School of Medicine18
Completed
Not Applicable
Clinical study of adjuvant immuno-cell therapy for pancreatic cancer curatively resectable.Pancreatic cancerJPRN-C000000414Yokohama City University Hospital10
Unknown
Phase 1
Phase I/II study of adoptive immunotherapy using cytotoxic T cells specific for minor histocompatibility antigen restricted to hematopoietic cells for patients with high-risk leukemia that relapsed following allogeneic hematopoietic stem cell transplantatio1) RAEB, CMML 2) AML or ALL in induction failure or beyond first remission 3) Ph/p190-positive ALL at any stage 4) imatinib-resistant CMJPRN-C000000162Aichi Cancer Center30
Completed
Phase 2
Prostate Cancer: An internal, solid-malignancy model for vaccine therapyHormone refractory prostate cancerCancer - ProstateACTRN12605000589684Queensland Institute of Medical Research (QIMR)30
Completed
Not Applicable
Phase I/IIa Study of Adoptive Immunotherapy Comprising 2-Methyl-3-Butenyl-1-Pyrophosphate-Stimulated Gamma Delta T Cells in Patients With PSA biochemical failure after radical prostatectomy.JPRN-UMIN000006617Tokyo Women's Medical University10